Search This Blog

Tuesday, September 8, 2026

Upstream Bio's verekitug cuts severe asthma exacerbations 56% with 100 mg quarterly dosing in Phase 2

Upstream Bio's verekitug cuts severe asthma exacerbations 56% with 100 mg quarterly dosing in Phase 2 VALIANT trial

  • Company reiterates plans to initiate Phase 3 trials in severe asthma and CRSwNP in Q1 2027.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)